1. Home
  2. LIXT vs RHE Comparison

LIXT vs RHE Comparison

Compare LIXT & RHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • RHE
  • Stock Information
  • Founded
  • LIXT 2005
  • RHE 1988
  • Country
  • LIXT United States
  • RHE United States
  • Employees
  • LIXT N/A
  • RHE N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • RHE Real Estate
  • Sector
  • LIXT Health Care
  • RHE Real Estate
  • Exchange
  • LIXT Nasdaq
  • RHE Nasdaq
  • Market Cap
  • LIXT 4.2M
  • RHE 3.5M
  • IPO Year
  • LIXT N/A
  • RHE 2006
  • Fundamental
  • Price
  • LIXT $1.62
  • RHE $1.57
  • Analyst Decision
  • LIXT
  • RHE
  • Analyst Count
  • LIXT 0
  • RHE 0
  • Target Price
  • LIXT N/A
  • RHE N/A
  • AVG Volume (30 Days)
  • LIXT 1.8M
  • RHE 27.3K
  • Earning Date
  • LIXT 11-12-2024
  • RHE 11-29-2024
  • Dividend Yield
  • LIXT N/A
  • RHE N/A
  • EPS Growth
  • LIXT N/A
  • RHE N/A
  • EPS
  • LIXT N/A
  • RHE N/A
  • Revenue
  • LIXT N/A
  • RHE $15,936,000.00
  • Revenue This Year
  • LIXT N/A
  • RHE N/A
  • Revenue Next Year
  • LIXT N/A
  • RHE N/A
  • P/E Ratio
  • LIXT N/A
  • RHE N/A
  • Revenue Growth
  • LIXT N/A
  • RHE N/A
  • 52 Week Low
  • LIXT $1.31
  • RHE $1.13
  • 52 Week High
  • LIXT $4.42
  • RHE $3.08
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 43.04
  • RHE 43.01
  • Support Level
  • LIXT $1.56
  • RHE $1.13
  • Resistance Level
  • LIXT $1.87
  • RHE $2.11
  • Average True Range (ATR)
  • LIXT 0.23
  • RHE 0.15
  • MACD
  • LIXT -0.03
  • RHE -0.04
  • Stochastic Oscillator
  • LIXT 8.33
  • RHE 44.90

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About RHE Regional Health Properties Inc.

Regional Health Properties Inc is a self-managed healthcare real estate investment company that invests in real estate purposed for senior living and long-term healthcare through facility lease and sub-lease transactions. It has two reportable segments real estate segment and the healthcare services segment. It derives the majority of its revenue from the healthcare services segment. Its portfolio of properties is diversified across various states, with concentrations in Georgia and Ohio.

Share on Social Networks: